Editas, Allergan Ink $90M CRISPR-Based Eye Drug Deal – GenomeWeb
MedCity News |
Editas, Allergan Ink $90M CRISPR-Based Eye Drug Deal
GenomeWeb Under the terms of the deal, Allergan subsidiary Allergan Pharmaceuticals International Limited will have exclusive options to license up to five of Editas' ocular drug candidates including LCA10, its preclinical treatment for Leber congenital … Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease Allergan and Editas announce $90M CRISPR deal |
